DeepMed Research

Trastuzumab Rezetecan

Generic Name: Trastuzumab Rezetecan

Clinical Trials

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2

Not yet recruiting

Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Interventions: Drug: SHR-A1811
Drug: Pertuzumab
Drug: Docetaxel
Drug: Carboplatin
Drug: Albumin-Paclitaxel
Drug: Trastuzumab

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 180

Registration Number: NCT06927180

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Phase 2

Not yet recruiting

Conditions: Gastric Cancer
HER2 + Gastric Cancer
PD-L1 Positive
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

Interventions: Drug: Trastuzumab
Drug: Capecitabine
Drug: Apatinib
Drug: Adebrelimab
Drug: SHR-A1811
Drug: Oxaliplatin
Drug: S-1
Drug: SHR-A1904
Drug: SHR-1701
Drug: zolbetuximab

First Posted Date: 2025-03-18

Last Posted Date: 2025-03-18

Lead Sponsor: China Medical University, China

Target Recruit Count: 140

Registration Number: NCT06881017

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Phase 1

Not yet recruiting

Conditions: Recurrent or Metastatic Cervical Cancer

Interventions: Drug: SHR-A1811
Drug: Adebelimab injection
Drug: Bevacizumab injection
Drug: SHR-8068
Drug: Cisplatin injection
Drug: Carboplatin injection

First Posted Date: 2025-03-05

Last Posted Date: 2025-03-05

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT06859775

Locations: 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

Phase 1

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: SHR-A1811
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2025-02-21

Last Posted Date: 2025-04-25

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 50

Registration Number: NCT06840002

Locations: 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

A Study of SHR-A1811 in Subjects With Ovarian Cancer

Phase 3

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Paclitaxel Injection
Drug: SHR-A1811
Drug: Doxorubicin Hydrochloride Liposome Injection
Drug: Gemcitabine Hydrochloride for Injection
Drug: Topotecan Hydrochloride for Injection

First Posted Date: 2025-02-14

Last Posted Date: 2025-03-24

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 300

Registration Number: NCT06828354

Locations: 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

Phase 2

Recruiting

Conditions: HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

Interventions: Drug: SHR-A1811
Drug: SHR-1316
Drug: SHR-8068

First Posted Date: 2025-01-16

Last Posted Date: 2025-03-06

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 54

Registration Number: NCT06778031

Locations: 🇨🇳
Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain Metastasis

Phase 1

Recruiting

Conditions: Breast Cancer Metastatic
Breast Cancer Brain Metastases

Interventions: Drug: SHR-A1811
Drug: Pyrotinib
Drug: Bevacizumab

First Posted Date: 2024-12-05

Last Posted Date: 2025-02-06

Lead Sponsor: Fudan University

Target Recruit Count: 74

Registration Number: NCT06718933

Locations: 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

Phase 1

Recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: SHR-A1811
Drug: Ritonavir
Drug: Itraconazole

First Posted Date: 2024-12-02

Last Posted Date: 2025-03-28

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT06710990

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Advanced Breast Cancer
Metastatic Breast Cancer
Triple Negative Breast Cancer (TNBC)
HER2-negative Breast Cancer
Breast Cancer

Interventions: Drug: SHR-A1811
Drug: SHR-A1921
Drug: SHR-A2009
Drug: SHR-A2102

First Posted Date: 2024-10-18

Last Posted Date: 2024-12-10

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT06649331

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

Phase 2

Not yet recruiting

Conditions: Untreated Early-stage or Locally Advanced Breast Cancer

Interventions: Drug: SHR-A1811
Drug: Adebrelimab

First Posted Date: 2024-09-12

Last Posted Date: 2024-09-12

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT06592625

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy